Belépés

NCT07748091Toboroz

EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT

The Relationship of EEG Microstate Parameters and Neuroinflammatory Biomarkers With Treatment Response in Patients With Treatment-Resistant Major Depressive Disorder Receiving Electroconvulsive Therapy

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. aug. 5.

Rövid összefoglaló (regiszter, angolul)

This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in patients diagnosed with Major Depressive Disorder who are resistant to at least two antidepressant treatments, using microstate analysis derived from resting-state electroencephalography (EEG) recordings. Within this scope, EEG recordings obtained before and after ECT will be compared to determine the relationships between changes in microstate parameters and inflammatory marker levels, clinical variables, and psychometric scale scores reflecting clinical improvement. Peripheral blood samples collected from the same patient group will be analyzed for complete blood count parameters as well as levels of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), soluble glycoprotein 130 (sgp-130), soluble interleukin-6 receptor (sIL-6R), interferon gamma-induced protein 10 kDa (IP-10), and C-reactive protein (CRP). In addition, inflammatory indices, including the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR), will be calculated. The association between baseline levels of these biomarkers and treatment response will be evaluated. Moreover, changes in biomarker levels following ECT will be statistically examined in relation to clinical scale scores and EEG microstate parameters. Although microstate analysis and inflammatory biomarkers have each been extensively investigated in psychiatric disorders, studies evaluating these two biomarkers together, particularly with the inclusion of healthy control participants, remain limited. In this regard, the present study aims to evaluate the effects of ECT on patients with treatment-resistant depression using objective neurophysiological indicators, to contribute to the understanding of the pathophysiology of depression at the level of brain networks, and to provide a scientific basis for the development of personalized treatment approaches in the future.

Állapot (regiszter)
Toboroz
Vizsgálattípus
Megfigyeléses
Résztvevők száma
62 (tervezett)
Első benyújtás
2026. júl. 5.
Kezdés
2026. jan. 1.
Elsődleges befejezés
2026. dec.
Fő szponzor
Istanbul University - Cerrahpasa
Betegségek
Depresszió
NCT-szám
NCT07748091

Mit vállalsz

  • Vizsgálat típusa: Megfigyeléses
  • Tervezett résztvevők: 62
  • 2026. jan. 1. és az elsődleges befejezés (2026. dec.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Myocardial infarction within the previous 3 months.
  • Cerebrovascular disease within the previous month.
  • Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month.
  • Current use of systemic corticosteroids, immunosuppressive agents, or other medications known to affect inflammatory biomarkers significantly.

Más betegség

  • Primary neurological disorders (e.g., dementia or traumatic brain injury).
  • Schizophrenia or other psychotic disorders.
  • Bipolar disorder diagnosis,
  • Cognitive impairment severe enough to prevent adequate cooperation during EEG recording.
  • Current alcohol or substance use disorder.
  • Active infectious disease.
  • Autoimmune or chronic inflammatory disorders.

Egyéb

  • Intracranial space-occupying lesions.
  • Increased intracranial pressure.
  • Unstable cerebral aneurysm.
  • Pheochromocytoma.

Kiket keres a vizsgálat

  • Patient Group
  • Age 18-60 years
  • Diagnosis of Major Depressive Disorder, current major depressive episode, according to DSM-5 criteria.
  • Clinical indication for electroconvulsive therapy (ECT).
  • Ability to provide written informed consent.
  • Willingness to participate in the study.
    • Healthy Control Group:
  • Age ≥55 years.
  • No current psychiatric disorder.
  • No known neurological disorder.
  • Good general physical health.
  • No current use of medications known to affect EEG activity or inflammatory biomarkers significantly.
  • Ability to provide written informed consent.
  • Willingness to participate in the study.

Életkor a regiszterben: 18 év – 60 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
İstanbul University- Cerrahpasa, Cerrahpasa Medicine Faculty, Psychiatry Department
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát		IstanbulTörökországToboroz

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.